IGF2BP3 and breast carcinoma: LDH release assay showed that METTL3-, IGF2BP3-knockdown and atezolizumab (anti-PD-L1) treatment increased the breast cancer cell sensitivity towards T-cell killing as compared to control groups, and these effects could be reversed by the overexpression of PD-L1 (Fig. 4a).